[go: up one dir, main page]

TR200103680T2 - IL-8 receptor antagonists. - Google Patents

IL-8 receptor antagonists.

Info

Publication number
TR200103680T2
TR200103680T2 TR2001/03680T TR200103680T TR200103680T2 TR 200103680 T2 TR200103680 T2 TR 200103680T2 TR 2001/03680 T TR2001/03680 T TR 2001/03680T TR 200103680 T TR200103680 T TR 200103680T TR 200103680 T2 TR200103680 T2 TR 200103680T2
Authority
TR
Turkey
Prior art keywords
chemokine
receptor antagonists
administering
alpha
compound
Prior art date
Application number
TR2001/03680T
Other languages
Turkish (tr)
Inventor
L. Widdowson Katherine
F. Veber Daniel
J. Jurewicz Anthony
C. Rutledge Melvin
P. Hertzberg Robert
M. Benson Gregory
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200103680T2 publication Critical patent/TR200103680T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)

Abstract

Bu bulus, kemokinin bir IL-8 alfa veya beta reseptörüne baglanan kemokin oldugu ve bir formül (I) bilesiginin veya bunun farmasötik olarak kabul edilebilir bir tuzunun etkin bir miktarinin uygulanmasini kapsayan, kemokin kaynakli bir hastaligin tedavisine yönelik bir metod sunmaktadir. Kemokin özellikle IL-8'dir.The present invention provides a method for the treatment of a chemokine-induced disease, in which the chemokine is chemokine binding to an IL-8 alpha or beta receptor, and comprising administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Chemokine is especially IL-8.

TR2001/03680T 1999-06-16 2000-06-15 IL-8 receptor antagonists. TR200103680T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13967599P 1999-06-16 1999-06-16

Publications (1)

Publication Number Publication Date
TR200103680T2 true TR200103680T2 (en) 2002-07-22

Family

ID=22487790

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03680T TR200103680T2 (en) 1999-06-16 2000-06-15 IL-8 receptor antagonists.

Country Status (20)

Country Link
EP (1) EP1185261A4 (en)
JP (1) JP2003501459A (en)
KR (1) KR20020010709A (en)
CN (1) CN1355697A (en)
AR (1) AR030391A1 (en)
AU (1) AU766083B2 (en)
BR (1) BR0010802A (en)
CA (1) CA2377341A1 (en)
CO (1) CO5200760A1 (en)
CZ (1) CZ20014471A3 (en)
HK (1) HK1044483A1 (en)
HU (1) HUP0201571A3 (en)
IL (1) IL145761A0 (en)
MX (1) MXPA01013004A (en)
NO (1) NO20016053L (en)
NZ (1) NZ514695A (en)
PL (1) PL352232A1 (en)
TR (1) TR200103680T2 (en)
WO (1) WO2000076495A1 (en)
ZA (1) ZA200109479B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
CA2493253A1 (en) * 2002-08-01 2004-02-12 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7326729B2 (en) * 2004-05-12 2008-02-05 Schering Corporation CXCR1 and CXCR2 chemokine antagonists
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
EP1809619A1 (en) 2004-10-21 2007-07-25 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
ATE499370T1 (en) 2005-01-19 2011-03-15 Bristol Myers Squibb Co 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDINE-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
DE602006017694D1 (en) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR SUITABLE FOR THE TREATMENT OF THROMBOTIC SUFFERING
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
KR20080027890A (en) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 N-linked heterocyclic antagonists of the P2Ｙ1 receptor useful for the treatment of thrombotic symptoms
ATE502924T1 (en) 2005-06-27 2011-04-15 Bristol Myers Squibb Co LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSIS
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008184403A (en) * 2007-01-29 2008-08-14 Japan Health Science Foundation Novel hepatitis C virus inhibitor
KR100982661B1 (en) * 2008-04-22 2010-09-17 전남대학교산학협력단 Pharmaceutical composition for the prevention and treatment of malaria containing a compound that inhibits plasmincin II activity as an active ingredient and a method for treating malaria using the same
KR100970940B1 (en) * 2010-05-03 2010-07-20 전남대학교산학협력단 Pharmaceutical composition for preventing and treating malaria comprising compounds that inhibit Plasmepsin II activity and the method of treating malaria using thereof
US10093617B1 (en) * 2015-10-30 2018-10-09 Sumitomo Chemical Company, Limited Method for producing 2-amino-4-substituted phenol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
JPH11503110A (en) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション IL-8 receptor antagonist
AU6035899A (en) * 1998-09-18 2000-04-10 Smithkline Beecham Corporation Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis

Also Published As

Publication number Publication date
WO2000076495A1 (en) 2000-12-21
CO5200760A1 (en) 2002-09-27
JP2003501459A (en) 2003-01-14
IL145761A0 (en) 2002-07-25
BR0010802A (en) 2002-02-19
CZ20014471A3 (en) 2002-08-14
AR030391A1 (en) 2003-08-20
AU5741300A (en) 2001-01-02
MXPA01013004A (en) 2002-07-30
CA2377341A1 (en) 2000-12-21
EP1185261A4 (en) 2004-02-25
NZ514695A (en) 2004-05-28
HUP0201571A2 (en) 2002-08-28
CN1355697A (en) 2002-06-26
EP1185261A1 (en) 2002-03-13
ZA200109479B (en) 2002-11-18
HK1044483A1 (en) 2002-10-25
NO20016053D0 (en) 2001-12-11
HUP0201571A3 (en) 2002-11-28
KR20020010709A (en) 2002-02-04
PL352232A1 (en) 2003-08-11
NO20016053L (en) 2001-12-11
AU766083B2 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
TR200103680T2 (en) IL-8 receptor antagonists.
ATE309249T1 (en) CHEMOKINE RECEPTOR ANTAGONISTS AND USES
BR9807876A (en) Heterocyclic compounds and their use for inhibition of beta-amyloid peptide
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
TR200100918T2 (en) Inhibition of RAF kinase using aryl and heteroaryl substituted ureas
BR0108977A (en) Azacyclic compounds for use in the treatment of serotonin-related diseases
TR199901710T2 (en) IL-8 receptor antagonists.
BR9714358A (en) Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds
DK0583421T3 (en) Substituted dibenzoxazepine compounds, drugs and methods of use
BR9812492A (en) Compound, use of it, pharmaceutical formulation, and processes for the treatment of cardiovascular disease, for the treatment of vasoconstriction, and for the preparation of compounds
TR200101633T2 (en) Pharmaceutical composition
TR200000786T2 (en) Vitronectin receptor antagonist
TR199901761T2 (en) IL-8 receptor antagonists.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
EA200000693A1 (en) ANTAGONISTS OF THE CHEMOKINE RECEPTOR AND METHODS OF THEIR APPLICATION
MXPA04004826A (en) Chemokine receptor antagonists and methods of use thereof.
EA200100140A1 (en) THERAPEUTIC COMPOSITION ON THE BASIS OF FLAVONOIDS FOR APPLICATION IN TREATMENT OF TUMORS BY CYTOTOXIC AGENTS
WO2001009119A3 (en) Chemokine receptor antagonists
WO2000076457A3 (en) Il-8 receptor antagonists
BR0213633A (en) Method and compound for treating a disease associated with aberrant leukocyte recruitment and / or activation
EA200401617A1 (en) COMBINATION OF NMDA ANTAGONIST AND ACETYL CHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALCHEIMER&#39;S Disease
ATE301997T1 (en) ANTIVIRAL THERAPY
TR200103690T2 (en) IL-8 receptor antagonists
TH13960A (en) Biologically compatible somatropropine solutions
TH24188A (en)